Hepatic Methionine Metabolism and S-adenosylmethionine (SAM) Homeostasis Dysregulation describes a family of situations in which the liver may no longer regulate methionine, S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), and connected one-carbon pathways in the usual way.

The pattern can involve reduced conversion of methionine into SAM, altered use of SAM, accumulation of S-adenosylhomocysteine (SAH), inadequate buffering of excess SAM, disturbed remethylation, altered transsulfuration, or several of these changes at the same time.

The liver is central to this topic because it metabolizes a large share of dietary methionine and contains highly active systems for producing and using SAM.

SAM supplies methyl groups for many reactions, including methylation of deoxyribonucleic acid, ribonucleic acid, proteins, phospholipids, glycine, and guanidinoacetate.

Once SAM donates a methyl group, it becomes SAH. SAH can inhibit many methyltransferases, so methylation capacity depends not only on how much SAM is available but also on how effectively SAH is removed.

This is not a uniform “low methylation” pattern.

Chronic liver disease may be associated with reduced methionine adenosyltransferase activity and lower hepatic SAM, but other disorders can produce high methionine, high SAM, high SAH, or mixed profiles.

Glycine N-methyltransferase deficiency, for example, is characterized by marked hypermethioninemia and very high SAM, while S-adenosylhomocysteine hydrolase deficiency produces a different pattern involving pronounced SAH accumulation.

These rare disorders demonstrate why a high or low value cannot be interpreted without locating the affected step.

Most people do not begin by suspecting hepatic methionine or SAM dysregulation. They usually begin with persistent fatigue, cognitive complaints, unexpected reactions to supplements, fatty liver found on imaging, elevated liver enzymes, or an amino-acid result that appears difficult to reconcile with homocysteine.

The liver-related hypothesis often emerges only after a person combines symptoms with a genetic report, an amino-acid panel, a SAM and SAH panel, or an unusual response to methionine, SAMe, choline, phosphatidylcholine, trimethylglycine, methylfolate, or vitamin B12.

The central interpretive task is therefore not to decide whether the person is an “overmethylator” or an “undermethylator.” It is to ask which part of hepatic methionine and SAM homeostasis may be altered, whether the change is primary or secondary, whether the measured markers actually reflect liver metabolism, and whether another organ, nutrient, disease process, medication, or pre-analytical issue offers a better explanation.

The phrase hepatic methionine and SAM dysregulation can sound more specific than it is.

It does not name one disease, one genotype, one symptom cluster, or one laboratory signature. It is a framework for organizing questions that arise when liver biology and methylation biology intersect.

A useful starting point is to identify what brought the question into view. In practice, people arrive through several different routes.

Some begin with a liver finding, such as steatosis on ultrasound, persistently elevated alanine aminotransferase, or an established chronic liver condition.

Others begin with a methylation-related result, such as high or low methionine, an unusual homocysteine concentration, a reported low SAM/SAH ratio, or a commercial report that labels methylation as impaired.

A third group begins with an experience, for example, a strong response to SAMe, worsening after methionine, variable reactions to trimethylglycine, or concern that protein-rich meals are producing anxiety, insomnia, fatigue, or cognitive changes.

These routes are not equivalent.

A liver diagnosis provides a clinical context, but it does not identify the direction of methionine-cycle change.

An amino-acid result provides a biochemical observation, but it does not prove that the liver caused it.

A supplement reaction provides information about tolerability, but it does not measure intracellular SAM, SAH, or methyltransferase activity.

Questions this chapter is designed to answer

This pattern is relevant when the underlying question resembles one of the following:

• Why is methionine high when homocysteine is low or normal?
• Why is methionine low despite adequate protein intake?
• Can liver dysfunction reduce the conversion of methionine to SAM?
• Can SAM be high while methylation capacity is still impaired?
• Does a low SAM/SAH ratio mean that more methyl donors are needed?
• Can fatty liver alter choline demand or phosphatidylcholine synthesis?
• Does elevated alanine aminotransferase mean that methylation is impaired?
• Can normal liver enzymes exclude meaningful liver-related changes?
• Does a PEMT, MAT1A, GNMT, BHMT, or MTHFR variant explain a laboratory result?
• Why does SAMe help initially but later produce insomnia, agitation, or a crash?
• Can protein intake or methionine-rich foods produce “overmethylation”?
• Is an unusual response to choline or trimethylglycine evidence of a liver problem?
• When should persistent hypermethioninemia be evaluated as a possible inherited disorder?
• How can kidney function, nutrition, medication, and sample handling distort interpretation?

The pattern is less useful when the only evidence is a broad symptom such as fatigue, brain fog, anxiety, low mood, or poor exercise tolerance.

These experiences are real, but they are not specific to methionine or SAM metabolism. They can occur with sleep disorders, endocrine conditions, anemia, infection, medication effects, nutritional inadequacy, metabolic disease, psychiatric conditions, and many other causes.

The purpose of this chapter is not to relabel nonspecific symptoms.

It is to help determine whether a liver-methionine-SAM question is biochemically coherent and what additional context is required.

A recurring sequence is:

1. Persistent symptoms or unexpected supplement reactions create a need for an explanation.
2. A laboratory, imaging, or genetic result supplies a biochemical term, such as methionine, homocysteine, fatty liver, PEMT, or SAM/SAH.
3. Online explanations connect that term to methylation.
4. The person begins to interpret food and supplement responses as confirmation of the proposed mechanism.
5. Conflicting results appear, for example, high methionine with low homocysteine, normal folate with a presumed methylation block, or improved energy with worsening sleep.

The difficulty begins at step four.

A response may be meaningful, but it is rarely specific. SAMe can affect neurotransmitter-related pathways, methylation reactions, glutathione metabolism, and polyamine synthesis.

Choline can support phosphatidylcholine synthesis and also contribute to acetylcholine and betaine pools.

Trimethylglycine can participate in betaine-homocysteine methyltransferase-dependent remethylation, but the effect depends on substrate availability, enzyme activity, nutritional state, and tissue context.

A strong reaction does not identify which of these pathways changed.

Routine liver tests are useful for identifying injury patterns and synthetic dysfunction, but they do not directly measure hepatic SAM production.

Alanine aminotransferase and aspartate aminotransferase can be normal in people with significant steatosis or fibrosis, and they can be elevated for reasons that do not involve primary methionine-cycle dysfunction.

Albumin, bilirubin, international normalized ratio, platelet count, imaging, and fibrosis assessment provide different kinds of information. No single routine marker reports the activity of methionine adenosyltransferase 1A, glycine N-methyltransferase, phosphatidylethanolamine N-methyltransferase, or S-adenosylhomocysteine hydrolase.

The reverse is also true.

A plasma methionine concentration does not provide a complete assessment of liver health.

Methionine is influenced by intake, fasting status, catabolism, remethylation, transsulfuration, genetic disorders, severe illness, and laboratory handling.

Persistent marked hypermethioninemia requires a different level of attention than a small isolated variation on a commercial amino-acid panel.

A person may have metabolic dysfunction-associated steatotic liver disease and an unusual homocysteine value.

That does not automatically mean the liver disease caused the homocysteine result.

Folate status, vitamin B12 status, vitamin B6 status, kidney function, thyroid function, alcohol exposure, medication, smoking, inflammation, and genetics may all contribute.

Similarly, a person may have a phosphatidylethanolamine N-methyltransferase (PEMT) variant and fatty liver.

That combination is biologically interesting because PEMT uses SAM to synthesize phosphatidylcholine in the liver, and phosphatidylcholine is important for very-low-density lipoprotein assembly and secretion.

However, common variants are modifiers, not stand-alone diagnoses. The presence of a variant does not establish that phosphatidylcholine synthesis is inadequate in that individual, and it does not prove that taking large doses of choline will correct the problem.

The pattern fits best when several layers converge:

• a plausible hepatic or metabolic context;
• a reproducible biochemical finding;
• a pathway-consistent relationship among markers;
• exclusion of major alternative explanations;
• and, when appropriate, specialist evaluation for persistent or marked abnormalities.

It does not mean that:

• every person with fatty liver has low SAM;
• every person with elevated liver enzymes has impaired methylation;
• high methionine means excessive dietary protein;
• low homocysteine proves accelerated transsulfuration;
• high SAM proves efficient methylation;
• low SAM means that SAMe supplementation is appropriate;
• a low SAM/SAH ratio identifies the treatment;
• a common genetic variant is equivalent to an inherited enzyme deficiency;
• improvement after a supplement confirms the suspected mechanism;
• worsening after a methyl donor proves “overmethylation.”

Some findings are not suitable for prolonged trial-and-error interpretation.

Persistent marked hypermethioninemia, especially when accompanied by neurologic findings, developmental concerns, hypotonia, unusual odor, coagulopathy, hepatomegaly, unexplained elevation of aminotransferases, or abnormal SAM and SAH concentrations, can require assessment for inborn errors of metabolism.

Consensus recommendations for inherited methylation disorders emphasize a structured differential that includes cystathionine beta-synthase deficiency, methionine adenosyltransferase I/III deficiency, glycine N-methyltransferase deficiency, S-adenosylhomocysteine hydrolase deficiency, and adenosine kinase deficiency.

Likewise, possible chronic liver disease should be assessed through established liver pathways rather than through methylation panels alone.

Modern liver guidelines use metabolic risk assessment, alcohol history, medication review, imaging, fibrosis risk tools, elastography when indicated, and specialist referral according to the level of risk.

The methylation cycle can add mechanistic understanding, but it does not replace standard liver evaluation.

Which measured or suspected step is abnormal, what evidence locates the problem at that step, and what other explanations could create the same pattern?

This question prevents several common errors.

It separates methionine availability from SAM production.

It separates SAM concentration from methylation flux.

It separates SAH accumulation from methyl-donor deficiency.

It separates choline need from PEMT genotype.

It separates liver injury from liver synthetic function.

Most importantly, it creates room for the possibility that more than one process is operating at the same time.

Understanding this pattern requires a map rather than a single marker.

Methionine does not simply “become methylation.” It enters a regulated cycle in which production, use, recycling, and disposal are coordinated.

The liver has a particularly large role because it handles a substantial share of dietary methionine and expresses specialized enzymes that allow methionine and SAM concentrations to respond to nutritional and metabolic conditions.

Step 1. Methionine enters the hepatic pool

Methionine is an essential sulfur-containing amino acid. It must be obtained from food, although the body can regenerate methionine from homocysteine through remethylation. After absorption, dietary amino acids enter the portal circulation and reach the liver. The liver uses methionine for protein synthesis, but a major fraction also enters the methionine cycle.

The concentration measured in plasma is the result of multiple processes:

• recent intake;
• fasting duration;
• protein turnover;
• hepatic uptake;
• conversion to SAM;
• regeneration from homocysteine;
• transsulfuration;
• renal and systemic metabolism.

This is why a plasma value cannot be read as a direct measure of dietary intake or liver enzyme activity.

Methionine availability matters, but more is not automatically better.

Severe methionine deficiency can limit protein synthesis and SAM production.

At the other extreme, persistent marked hypermethioninemia can be a sign of impaired methionine handling, inherited enzyme defects, severe liver dysfunction, or other metabolic disturbances.

The interpretation depends on magnitude, persistence, age, symptoms, and the accompanying pattern of homocysteine, SAM, SAH, liver tests, and other amino acids.

Step 2. Methionine is converted into S-adenosylmethionine

Methionine is activated to form SAM in a reaction that uses adenosine triphosphate. The reaction is catalyzed by methionine adenosyltransferase (MAT).

In normal differentiated adult liver, the dominant catalytic subunit is encoded by methionine adenosyltransferase 1A (MAT1A). MAT1A forms the MAT I and MAT III isoenzymes.

Extrahepatic tissues and proliferating or dedifferentiated liver cells more commonly express methionine adenosyltransferase 2A (MAT2A), with regulation by methionine adenosyltransferase 2B (MAT2B).

This distinction is not merely a naming detail. MAT I, MAT III, and MAT II differ in kinetic behavior and regulation. The adult liver needs to accommodate large changes in methionine delivery after meals. MAT III becomes more active as methionine rises, helping the liver convert excess methionine into SAM. This contributes to the liver’s buffering function.

In chronic liver injury, a shift from MAT1A toward MAT2A and MAT2B expression has repeatedly been described. This switch is associated with hepatocyte dedifferentiation, proliferation, fibrosis, and hepatocellular carcinoma biology.

It does not mean that every person with mild steatosis has a complete MAT1A-to-MAT2A switch, but it provides a mechanistic explanation for why chronic liver disease can change SAM homeostasis.

Step 3. SAM is distributed among competing demands

SAM is commonly called the universal methyl donor because it provides methyl groups to a very large number of methyltransferases.

In the liver, important SAM-dependent demands include:

• methylation of deoxyribonucleic acid, ribonucleic acid, histones, and other proteins;
• conversion of phosphatidylethanolamine to phosphatidylcholine through PEMT;
• methylation of glycine through glycine N-methyltransferase (GNMT);
• methylation of guanidinoacetate during creatine synthesis;
• synthesis and regulation of small molecules and signaling intermediates;
• decarboxylated SAM-dependent polyamine synthesis.

These reactions do not all have the same priority, tissue distribution, or response to SAM availability. A change in SAM concentration can therefore redistribute methyl-group use rather than producing a uniform change in all methylation reactions.

This is one reason the phrase “methylation is high” is often misleading.

Deoxyribonucleic acid methylation may decrease in one genomic region and increase in another.

Phospholipid methylation may be constrained while other pathways continue.

A tissue can preserve essential reactions at the expense of less protected reactions. Measurement of plasma SAM cannot resolve these tissue- and substrate-specific effects.

Step 4. SAM becomes S-adenosylhomocysteine

After donating its methyl group, SAM becomes SAH.

SAH is not merely an inactive waste product. It is a potent product inhibitor of many SAM-dependent methyltransferases. As SAH rises, the thermodynamic and enzymatic environment for methyl-group transfer becomes less favorable.

For this reason, the relationship between SAM and SAH is often described as methylation potential. The SAM/SAH ratio can be informative in research and selected clinical contexts, but it is not a universal diagnostic threshold.

Ratios vary by:

• specimen type;
• analytical method;
• sample processing;
• disease state;
• laboratory reference interval.

A ratio also hides absolute values. The same ratio can arise from low SAM and low SAH, normal SAM and elevated SAH, or high concentrations of both.

A person can therefore have a normal or elevated SAM concentration while methyltransferase activity is constrained by SAH.

Conversely, a lower SAM concentration does not necessarily mean all methylation reactions have failed.

The interpretation must consider both metabolites and the biological context.

Step 5. SAH is hydrolyzed to homocysteine and adenosine

S-adenosylhomocysteine hydrolase, encoded by AHCY, catalyzes the reversible conversion between SAH and homocysteine plus adenosine.

Although the reaction is reversible, effective removal of homocysteine and adenosine normally pulls it toward SAH hydrolysis.

This point is crucial. SAH clearance depends on what happens downstream. If homocysteine and adenosine accumulate, the reaction can become less favorable, allowing SAH to rise.

Kidney dysfunction is relevant because renal disease can alter homocysteine, SAH, SAM, and related metabolites.

Adenosine metabolism is also relevant, illustrated dramatically by adenosine kinase deficiency, in which disruption of adenosine handling affects the methionine cycle and can produce hypermethioninemia and liver dysfunction.

The concentration of homocysteine is therefore not a simple readout of how much SAH has been produced.

Homocysteine can be remethylated, directed into transsulfuration, exported, or affected by renal clearance and nutritional status.

A low homocysteine concentration does not prove that SAH is low, and a high homocysteine concentration does not identify the liver as the primary cause.

Step 6. Homocysteine is remethylated to methionine

Homocysteine can return to methionine through two major remethylation routes.

The folate- and vitamin B12-dependent route is catalyzed by methionine synthase. It uses 5-methyltetrahydrofolate as the methyl donor and methylcobalamin as a cofactor. This route operates in many tissues.

The betaine-dependent route is catalyzed by betaine-homocysteine methyltransferase (BHMT), expressed strongly in the liver and kidney.

Betaine donates a methyl group to homocysteine, producing methionine and dimethylglycine. Betaine can arise from the oxidation of choline or from dietary sources.

These routes help preserve methionine and support SAM production, but they also interact. If folate-dependent remethylation is constrained, BHMT may become more important.

If choline is diverted toward phosphatidylcholine synthesis or acetylcholine-related needs, betaine availability may change.

If liver expression of BHMT falls during injury, the apparent availability of betaine may not translate into the expected remethylation response.

This is why taking trimethylglycine is not equivalent to taking SAMe.

Trimethylglycine may support one route that regenerates methionine from homocysteine.

It still depends on BHMT activity, homocysteine availability, and the capacity to convert the resulting methionine into SAM.

SAMe bypasses the methionine-to-SAM step but enters a much broader network and can affect multiple pathways rapidly.

Step 7. Homocysteine enters transsulfuration

Homocysteine can also be directed through transsulfuration.

Cystathionine beta-synthase combines homocysteine with serine to form cystathionine.

Cystathionine gamma-lyase then contributes to the formation of cysteine.

Both enzymes depend on vitamin B6 in its active form, pyridoxal 5′-phosphate.

Cysteine can support:

• protein synthesis;
• glutathione production;
• taurine-related metabolism;
• sulfate generation;
• other sulfur pathways.

The liver has a major role in transsulfuration and glutathione homeostasis.

During oxidative stress or liver injury, demand for glutathione may change, but the direction of plasma markers is not always predictable because synthesis, utilization, export, and breakdown can all change.

SAM itself participates in regulation of this branch. Higher SAM can activate cystathionine beta-synthase and inhibit methylenetetrahydrofolate reductase, favoring transsulfuration over folate-dependent remethylation under methionine-replete conditions.

This is an elegant homeostatic design. When methionine and SAM are abundant, the system can direct more homocysteine toward sulfur disposal and glutathione-related pathways. When methionine is scarce, lower SAM reduces this signal and helps preserve remethylation.

However, this regulatory model is not a diagnostic shortcut. Low plasma homocysteine does not, by itself, prove excessive transsulfuration, and high SAM in plasma does not establish that hepatic cystathionine beta-synthase is overactive.

Step 8. GNMT buffers hepatic SAM

Glycine N-methyltransferase is one of the most abundant hepatic methyltransferases.

It transfers a methyl group from SAM to glycine, producing sarcosine and SAH.

This may appear wasteful, but GNMT serves as a major buffer for the hepatic SAM pool. When SAM rises, GNMT can consume more SAM and help stabilize the SAM/SAH environment.

GNMT is regulated by 5-methyltetrahydrofolate, which binds and inhibits the enzyme. This links folate status to the rate at which the liver dissipates excess SAM.

When folate-dependent methyl supply is lower, GNMT inhibition can lessen, allowing more SAM consumption.

When folate status is higher, GNMT inhibition may help conserve SAM.

The exact response is context-dependent, but the relationship illustrates how folate and hepatic SAM homeostasis communicate.

Loss of GNMT function produces a strikingly different phenotype from reduced MAT1A activity.

Human GNMT deficiency is rare and is characterized by marked hypermethioninemia, high SAM, relatively normal SAH in reported cases, and liver abnormalities such as hepatomegaly or elevated aminotransferases.

In mice, loss of GNMT causes chronic SAM excess, altered methylation, fatty liver, fibrosis, and hepatocellular carcinoma. These observations show that excessive hepatic SAM can be harmful and that “more methyl donor” is not a universal solution.

Step 9. PEMT connects methylation to phosphatidylcholine and lipid export

Phosphatidylethanolamine N-methyltransferase converts phosphatidylethanolamine to phosphatidylcholine through three sequential SAM-dependent methylation reactions. The pathway is concentrated in the liver.

Phosphatidylcholine is required for:

• cell membranes;
• bile;
• assembly and secretion of very-low-density lipoprotein particles.

The liver also makes phosphatidylcholine through the cytidine diphosphate-choline pathway, which uses preformed choline. The two pathways are complementary.

When dietary choline is low or endogenous PEMT activity is inadequate for demand, phosphatidylcholine availability can become limiting. In controlled human choline-depletion studies, susceptible participants developed increased liver fat or liver and muscle injury, and abnormalities improved when choline was restored.

This is one of the strongest human examples showing that nutrient availability, genetic variation, sex, hormonal state, and hepatic lipid handling can interact. It does not prove that all metabolic fatty liver is caused by choline deficiency, but it explains why choline and methyl-group demand can be relevant in selected contexts.

PEMT also creates a substantial SAM demand. Each phosphatidylcholine molecule formed through PEMT requires three methyl transfers and generates three molecules of SAH. The pathway therefore affects both sides of methylation potential: it consumes SAM and produces SAH.

A person can theoretically have high phosphatidylcholine demand, inadequate choline intake, and pressure on SAM-dependent synthesis, but this cannot be inferred from a PEMT single-nucleotide polymorphism alone.

Step 10. Creatine synthesis is another major methyl-group demand

Guanidinoacetate methyltransferase uses SAM to convert guanidinoacetate into creatine. The liver contributes substantially to systemic creatine synthesis. Endogenous creatine production has often been described as a major consumer of labile methyl groups.

This creates another interaction that is easy to oversimplify. Creatine supplementation can reduce the need for endogenous creatine synthesis in some settings, which may spare methyl groups.

However, the effect on a person’s symptoms, homocysteine, SAM, or liver status depends on baseline diet, renal function, muscle mass, dose, and other factors. Creatine response cannot diagnose high SAM demand, and creatine is not a treatment for an undefined methylation disorder.

Step 11. SAM also enters polyamine synthesis and transsulfuration support

SAM can be decarboxylated and used in polyamine synthesis. This pathway is important for cell growth, regeneration, and proliferation. Changes in MAT1A, MAT2A, MAT2B, and decarboxylated SAM metabolism are relevant in chronic liver injury and hepatocellular carcinoma research.

SAM also supports glutathione homeostasis indirectly by supplying homocysteine to transsulfuration. In alcohol-related liver injury and other models, reduced hepatic SAM has been linked to impaired mitochondrial glutathione.

Yet supplementing SAMe does not automatically reverse the underlying disease, and clinical trials have produced mixed results depending on population, severity, duration, abstinence, and outcome.

Homeostasis does not mean keeping SAM at the highest possible concentration.

It means maintaining a workable relationship among:

• methionine supply;
• MAT-dependent SAM production;
• methyltransferase demand;
• GNMT buffering;
• SAH hydrolysis;
• homocysteine remethylation;
• transsulfuration;
• adenosine removal;
• phosphatidylcholine and creatine synthesis;
• redox and glutathione needs;
• cell growth and regeneration.

A disturbance at any one point can alter the others.

The same plasma methionine value may therefore arise from very different mechanisms.

The goal is not to assign a global label.

The goal is to identify the most plausible node and the evidence supporting it.

The central mistake in this topic is to imagine one hepatic methylation phenotype.

In reality, the direction of change depends on which reaction is affected.

The same symptom, such as fatigue or brain fog, can occur in several forms and cannot distinguish them.

Even the same marker can have different meanings depending on the surrounding pattern.

The five forms below are not formal diagnoses. They are mechanistic categories that help organize evidence.

The core problem

Methionine is available, but the liver's ability to convert it into S-adenosylmethionine (SAM) is reduced relative to demand.

This may occur when methionine adenosyltransferase 1A (MAT1A) expression or activity falls, when oxidative or nitrosative stress inhibits methionine adenosyltransferase activity, when hepatocytes lose their differentiated MAT1A-dominant state, or when severe liver dysfunction disrupts energy and substrate handling.

Chronic liver disease studies and experimental models have repeatedly described reduced methionine adenosyltransferase activity and lower hepatic SAM.

A shift from MAT1A toward methionine adenosyltransferase 2A (MAT2A) and methionine adenosyltransferase 2B (MAT2B) expression is associated with liver injury, proliferation, fibrosis, and hepatocellular carcinoma. In alcohol-related liver disease, oxidative stress and altered methionine metabolism can further impair SAM and glutathione homeostasis.

What the laboratory pattern might look like

There is no required plasma profile.

Possible findings include:

• normal or elevated methionine with relatively low SAM;
• low SAM with normal or elevated S-adenosylhomocysteine (SAH);
• a reduced SAM/SAH ratio;
• elevated homocysteine if remethylation or downstream handling is also impaired;
• apparently normal homocysteine if routing and clearance remain adequate;
• liver-related abnormalities that vary with disease severity.

The phrase “methionine is high, so SAM must be high” is therefore unsafe.

If conversion is constrained, methionine can accumulate while SAM supply remains inadequate.

Conversely, low methionine and low SAM could reflect low intake, malabsorption, catabolism, or impaired remethylation rather than a primary hepatic methionine adenosyltransferase problem.

What it may be confused with

• low protein or methionine intake;
• folate- or vitamin B12-dependent remethylation limitation;
• betaine-homocysteine methyltransferase-related remethylation limitation;
• renal changes affecting SAM, SAH, and homocysteine;
• sample-handling problems;
• commercial algorithm estimates that do not directly measure SAM.

Why supplement response is not diagnostic

A person may feel better after S-adenosylmethionine supplementation, commonly called SAMe, because it bypasses the methionine-to-SAM step, but this is not proof of MAT1A impairment.

SAMe can influence mood-related pathways and may have pharmacologic effects independent of a documented hepatic deficiency.

A person may also feel worse because of gastrointestinal effects, activation, sleep disruption, medication interactions, or changes in downstream demand.

Strength of evidence

Reduced hepatic SAM in established chronic liver disease is supported by mechanistic and human tissue evidence. The use of symptoms or an isolated consumer test to identify reduced hepatic SAM production is not established.

The core problem

SAM is produced and used, but SAH is not cleared efficiently enough. Because SAH inhibits many methyltransferases, methyl-group transfer can become constrained even when SAM is normal or high.

SAH may rise when its hydrolysis is limited, when homocysteine and adenosine are not removed effectively, when renal function is impaired, or when methyltransferase flux produces SAH faster than it can be cleared.

Rare S-adenosylhomocysteine hydrolase deficiency provides an extreme human example. More common liver and kidney conditions may produce milder and more complex changes.

What the laboratory pattern might look like

• elevated SAH;
• normal or elevated SAM;
• a reduced SAM/SAH ratio;
• variable methionine;
• variable homocysteine;
• possible elevation of both SAM and SAH in renal dysfunction or systemic disease.

This form explains why a normal SAM result cannot rule out reduced methylation potential. It also explains why adding more methyl donors may fail to correct the problem.

If the dominant constraint is product inhibition by SAH, increasing SAM supply may not restore normal flux and may increase downstream burden.

The ratio problem

The SAM/SAH ratio is often treated as a single verdict. That is a mistake.

Consider three conceptual profiles:

• SAM 40, SAH 10, ratio 4;
• SAM 400, SAH 100, ratio 4;
• SAM 8, SAH 2, ratio 4.

The ratio is the same, but absolute concentrations and likely contexts are very different. Laboratories also use different units, matrices, and methods.

Interpretation requires:

• the actual values;
• reference intervals;
• sample type;
• processing conditions;
• kidney function;
• liver context;
• the clinical question.

What it may be confused with

• low SAM supply;
• high methyl-group demand;
• renal retention of one-carbon metabolites;
• a transient postprandial or pre-analytical effect;
• inherited S-adenosylhomocysteine hydrolase or adenosine-related disorders;
• a nonspecific “undermethylation” label.

Strength of evidence

SAH inhibition of methyltransferases is established biochemistry. The clinical meaning of a mildly altered plasma ratio in a generally well adult is less certain and depends heavily on analytical quality and context.

The core problem

SAM production is intact or increased, but the liver does not use or buffer SAM normally.

Glycine N-methyltransferase (GNMT) is central to this category because it consumes SAM and helps stabilize hepatic methyl-group balance.

Reduced GNMT activity can allow SAM to rise markedly.

Human GNMT deficiency is rare, but it demonstrates the principle.

Reported patients have had:

• pronounced hypermethioninemia;
• very high SAM;
• relatively normal SAH;
• hepatomegaly;
• variable liver enzyme abnormalities.

Experimental GNMT deficiency produces chronic SAM excess, altered methylation, steatosis, fibrosis, and hepatocellular carcinoma.

Why high SAM does not mean “excellent methylation”

A high pool can reflect reduced use, altered compartmentation, or defective buffering. The presence of substrate does not prove that each methyltransferase is functioning effectively.

Chronic SAM excess can also change gene regulation and metabolic routing. Homeostasis requires balance, not maximal concentration.

Possible laboratory clues

• high methionine;
• markedly high SAM;
• SAH that is normal or less elevated than SAM;
• a high SAM/SAH ratio in some rare contexts;
• elevated aminotransferases or hepatomegaly;
• low sarcosine could be considered mechanistically, although it is not a stand-alone diagnostic marker.

What it may be confused with

• high dietary methionine;
• “overmethylation” inferred from anxiety or insomnia;
• MAT1A deficiency, which more often involves impaired conversion and hypermethioninemia but not the same SAM pattern;
• laboratory error or poor sample handling;
• supplementation with SAMe or methionine shortly before testing.

Strength of evidence

GNMT deficiency and GNMT-knockout models provide strong proof that excess SAM can be pathologic. Extrapolation from common GNMT variants or symptom reactions to a functional GNMT deficiency is speculative.

The core problem

Methionine remains persistently elevated because conversion, downstream use, or connected metabolic pathways are impaired. Persistent hypermethioninemia is a biochemical finding with a structured differential, not a diagnosis by itself.

Possible causes include:

• methionine adenosyltransferase I/III deficiency due to MAT1A variants;
• glycine N-methyltransferase deficiency;
• S-adenosylhomocysteine hydrolase deficiency;
• adenosine kinase deficiency;
• cystathionine beta-synthase deficiency, which usually has elevated homocysteine;
• severe liver disease;
• high methionine exposure or nutritional formulas;
• transient neonatal or illness-related changes;
• pre-analytical and analytical factors.

Why homocysteine is a key discriminator

Marked hypermethioninemia with high total homocysteine raises concern for cystathionine beta-synthase deficiency and related disorders.

Isolated hypermethioninemia with normal or near-normal total homocysteine points toward a different group, including:

• MAT1A deficiency;
• GNMT deficiency;
• S-adenosylhomocysteine hydrolase deficiency;
• adenosine kinase deficiency;
• liver-related causes.

SAM and SAH can further differentiate these conditions.

MAT1A deficiency typically reduces the ability to synthesize SAM from methionine.

GNMT deficiency produces very high SAM. S-adenosylhomocysteine hydrolase deficiency produces marked SAH elevation, often with elevated SAM.

Adenosine kinase deficiency disrupts adenosine removal and can affect both the methionine cycle and liver function.

Clinical range

Some heterozygous dominant MAT1A variants produce mild persistent isolated hypermethioninemia and few or no symptoms.

More severe biallelic forms can be associated with:

• neurologic abnormalities;
• white matter changes;
• developmental problems;
• unusual odor.

The relationship between methionine level and risk is not perfectly linear, but persistent high values, especially very high values, warrant specialist interpretation.

What it may be confused with

• a high-protein diet;
• a single mildly high result after a meal;
• “overmethylation”;
• common MTHFR variants;
• a presumed need to restrict methionine without diagnostic clarification.

Strength of evidence

The differential and diagnostic approach for inherited methylation disorders are addressed in consensus recommendations. Self-directed methionine restriction based on a single amino-acid panel is not supported.

The core problem

In common chronic liver disease, several pathway nodes may change at the same time.

Possible changes include:

• reduced MAT1A;
• increased MAT2A and MAT2B;
• altered GNMT expression;
• altered betaine-homocysteine methyltransferase expression;
• oxidative inhibition of enzyme activity;
• changed phosphatidylcholine demand;
• increased glutathione-related demand;
• less efficient SAH handling.

The resulting profile is mixed rather than cleanly classifiable.

This form is probably the most relevant to adults with:

• metabolic dysfunction-associated steatotic liver disease;
• alcohol-related liver disease;
• fibrosis;
• cirrhosis;
• cholestatic disease;
• hepatocellular carcinoma.

It is also the form most likely to be oversimplified by functional interpretations.

Possible findings

• normal, high, or low methionine;
• altered SAM and SAH in either direction;
• a reduced SAM/SAH ratio in some studies;
• increased serum SAM, SAH, and homocysteine in some metabolic liver cohorts;
• altered choline, betaine, dimethylglycine, cystathionine, and glutathione-related markers;
• liver enzymes that do not reliably indicate fibrosis severity;
• imaging or fibrosis markers that provide more clinically relevant information than methylation panels.

Why studies can appear contradictory

One study may measure hepatic tissue, while another measures plasma. One may include early steatosis, while another includes cirrhosis.

Additional differences include:

• fasting status;
• medication;
• kidney function;
• diabetes;
• alcohol exposure;
• sex;
• menopausal status;
• choline intake;
• genetic background.

A rise in serum SAM in one cohort does not contradict lower hepatic SAM in another disease stage.
Circulating and intracellular compartments are not interchangeable.

What it may be confused with

• a primary inherited methylation disorder;
• isolated folate or vitamin B12 deficiency;
• renal retention;
• a single “methylation block”;
• supplement-induced changes;
• dietary insufficiency.

Strength of evidence

Methionine-cycle remodeling in chronic liver disease is strongly supported as a mechanistic phenomenon. The use of a standardized “hepatic methylation panel” to diagnose this mixed form in routine practice is not established.

These categories are not permanent identities.

A person with metabolic fatty liver may initially have compensatory high circulating SAM and SAH, later develop reduced MAT1A activity with advanced disease, and also experience renal changes that raise SAH.

Nutritional restriction can superimpose low methionine availability. Supplement use can temporarily change measured pools. Disease stage and intervention matter.

The chapter therefore uses the term pattern in a dynamic sense. It describes a configuration of pathway pressures, not a lifelong trait.

A biochemical pathway does not operate in isolation.

Hepatic methionine and SAM homeostasis respond to:

• the condition of the hepatocyte;
• energy availability;
• redox state;
• nutrient supply;
• hormonal signaling;
• kidney function;
• medication exposure;
• the balance between lipid synthesis and export.

This block examines contexts that can modify the cycle without implying that each context produces the same laboratory signature.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the preferred term for the condition previously called non-alcoholic fatty liver disease in major international guidance.

It is defined within a broader cardiometabolic context and is strongly associated with:

• insulin resistance;
• central adiposity;
• dyslipidemia;
• type 2 diabetes;
• other metabolic risk factors.

MASLD is highly relevant to methylation interpretation because the liver is simultaneously managing:

• excess lipid delivery;
• de novo lipogenesis;
• mitochondrial substrate oxidation;
• oxidative stress;
• phospholipid synthesis;
• very-low-density lipoprotein export.

One-carbon metabolites participate in several of these processes, but there is no single MASLD methylation profile.

Human studies have reported altered serum methionine-cycle metabolites in MASLD, including higher SAM, SAH, and homocysteine in some cohorts.

Tissue and experimental studies have also described:

• reduced MAT1A;
• altered GNMT expression;
• altered S-adenosylhomocysteine hydrolase expression;
• changes in phosphatidylcholine metabolism;
• epigenetic remodeling.

These observations are biologically coherent but heterogeneous. Disease stage, obesity, diabetes, diet, medication, and kidney function differ across studies.

The most important clinical point is that methylation markers do not replace established MASLD risk assessment.

Alanine aminotransferase can be normal even when clinically relevant fibrosis is present. Contemporary guidelines use:

• metabolic risk factors;
• fibrosis scores such as Fibrosis-4 Index;
• elastography or other non-invasive testing when indicated;
• referral pathways based on fibrosis risk.

A person should not be reassured by a normal homocysteine or alarmed by a single amino-acid value while ignoring the broader liver assessment.

As steatosis progresses to steatohepatitis and fibrosis, hepatocyte stress, inflammation, mitochondrial dysfunction, and changes in cellular differentiation become more prominent.

Possible changes include:

• reduced MAT1A expression and activity;
• increased MAT2A and MAT2B expression;
• reduced GNMT;
• reduced betaine-homocysteine methyltransferase;
• oxidative and nitrosative inhibition of methionine adenosyltransferase;
• altered SAH handling;
• changed glutathione-related demand.

Advanced cirrhosis adds further complications:

• reduced functional liver mass;
• altered portal flow;
• malnutrition;
• sarcopenia;
• inflammation;
• infection risk;
• medication burden;
• kidney dysfunction.

Each of these can affect methionine-cycle markers. A result that seems to indicate low SAM supply may be only one component of a broader loss of metabolic reserve.

In this setting, the clinically meaningful questions are not limited to methylation. They include:

• synthetic function;
• portal hypertension;
• nutritional status;
• muscle loss;
• renal function;
• complications of cirrhosis.

The methionine cycle can explain part of the biology, but it should not become the organizing diagnosis.

Alcohol affects hepatic methionine metabolism through several mechanisms.

Acetaldehyde and oxidative stress can impair methionine adenosyltransferase activity. Chronic alcohol exposure can:

• reduce MAT1A expression;
• lower hepatic SAM;
• disturb the SAM/SAH relationship;
• impair mitochondrial glutathione.

Folate deficiency, poor dietary intake, intestinal changes, and medication use may add further pressure.

The mechanistic rationale for SAMe in alcohol-related liver disease is therefore plausible. Clinical evidence, however, is mixed.

An older two-year randomized trial in alcoholic cirrhosis suggested a possible benefit in a subgroup with less advanced disease. A later randomized trial in alcohol-related liver disease found that abstinence improved liver function, but SAMe was not more effective than placebo over 24 weeks. Systematic reviews have emphasized heterogeneity and limitations in the evidence.

This is a useful example of the distinction between pathway logic and treatment proof.

A pathway may be altered, and a compound may replenish a relevant metabolite, yet clinical outcomes may still depend more strongly on:

• removal of the primary injury;
• disease stage;
• dose;
• bioavailability;
• other care.

For readers, the practical lesson is that a strong response to SAMe does not establish alcohol-related SAM deficiency, and lack of response does not disprove altered methionine metabolism.

Alcohol history remains a core part of liver evaluation regardless of methylation markers.

SAMe has been studied in several cholestatic settings, partly because it participates in:

• phospholipid metabolism;
• membrane function;
• glutathione-related pathways.

Some studies and reviews report improvement in biochemical markers or pruritus in selected forms of intrahepatic cholestasis.

Evidence quality varies, and other established therapies may be more effective depending on the condition.

Cholestasis can alter:

• bile composition;
• hepatocyte membrane stress;
• nutrient absorption;
• liver enzyme patterns.

Elevated alkaline phosphatase and gamma-glutamyl transferase raise a different diagnostic question from isolated mild alanine aminotransferase elevation.

A methylation interpretation should never delay evaluation of:

• biliary obstruction;
• autoimmune cholestatic disease;
• medication-related cholestasis;
• pregnancy-related cholestasis;
• genetic cholestatic disease.

The MAT1A-to-MAT2A switch is especially prominent in hepatocellular carcinoma research.

Reduced MAT1A and altered MAT2A/MAT2B signaling are associated with:

• proliferation;
• survival pathways;
• genomic instability;
• changes in methylation.

Loss of GNMT is also linked to hepatocarcinogenesis in experimental models and human tumor biology.

This literature provides powerful evidence that SAM homeostasis matters for liver-cell identity and growth.

It should not be translated into the claim that taking SAMe prevents cancer or that a consumer MAT1A variant predicts hepatocellular carcinoma.

Cancer biology involves:

• somatic changes;
• chronic inflammation;
• fibrosis;
• viral hepatitis;
• alcohol;
• metabolic disease;
• environmental exposures;
• many interacting pathways.

Methionine activation requires adenosine triphosphate.

Hepatic energy state therefore matters.

Insulin resistance changes substrate delivery and signaling, while mitochondrial dysfunction can alter energy production and redox balance.

These changes may influence:

• SAM synthesis;
• methyltransferase demand;
• lipid handling.

Insulin resistance also shifts the context in which choline and phosphatidylcholine pathways operate.

The liver may need to package more triglyceride into very-low-density lipoprotein while simultaneously receiving more fatty acids and producing more lipid.

Inadequate phosphatidylcholine availability can worsen lipid export, but excess very-low-density lipoprotein secretion also contributes to atherogenic dyslipidemia. The goal is not maximal export at any cost. It is coordinated metabolic function.

Questions about SAM, choline, and fatty liver should therefore include:

• fasting glucose;
• glycated hemoglobin;
• triglycerides;
• waist-related risk;
• blood pressure;
• medication;
• diet;
• activity;
• sleep.

A methylation supplement cannot compensate for an unaddressed metabolic environment.

Methionine metabolism connects to glutathione through homocysteine and transsulfuration.

During oxidative stress, demand for cysteine and glutathione may increase. The liver may direct more sulfur toward antioxidant defense, but chronic injury can also impair synthesis, mitochondrial transport, or recycling.

It is tempting to infer this entire process from:

• low cysteine;
• low homocysteine;
• a reaction to N-acetylcysteine.

Such inferences are weak without context.

Plasma cysteine and cystine are affected by:

• oxidation during sample handling;
• dietary intake;
• protein turnover;
• systemic metabolism.

N-acetylcysteine has pharmacologic actions beyond supplying cysteine. Glutathione status in blood does not necessarily represent mitochondrial glutathione in hepatocytes.

The robust conclusion is that redox demand and methionine metabolism are connected.

The unsupported conclusion is that one symptom or one sulfur marker proves “drainage” of methionine through transsulfuration.

Choline is an essential nutrient with several roles.

It is used to:

• synthesize phosphatidylcholine through the cytidine diphosphate-choline pathway;
• produce betaine for betaine-homocysteine methyltransferase-dependent remethylation;
• contribute to acetylcholine synthesis.

These uses can compete under conditions of limited supply.

Controlled human depletion-repletion studies provide unusually direct evidence. When participants consumed a low-choline diet, susceptible individuals developed:

• increased liver fat;
• elevated aminotransferases;
• muscle injury.

Abnormalities improved when choline was restored.

Susceptibility differed according to:

• sex;
• menopausal status;
• common genetic variants in choline and one-carbon pathways.

This evidence supports the existence of variable choline requirements.

It does not support diagnosing choline deficiency from:

• brain fog;
• fatty liver;
• a PEMT variant alone.

Dietary intake must be assessed, and high-dose supplementation has its own tolerability and metabolic considerations.

The relationship with SAM is bidirectional. Phosphatidylethanolamine N-methyltransferase uses three SAM-dependent methyl transfers to form one phosphatidylcholine molecule.

When choline intake is low, reliance on phosphatidylethanolamine N-methyltransferase-derived phosphatidylcholine may increase, potentially increasing methyl-group demand.

At the same time, choline oxidation to betaine can support homocysteine remethylation.

Whether supplemental choline or betaine is helpful depends on which branch is constrained and whether the liver can use the substrate normally.

Protein intake is one of the most emotionally charged parts of this topic.

People may begin to fear:

• eggs;
• meat;
• fish;
• legumes;
• protein supplements.

This often happens after reading that methionine can raise homocysteine or accelerate aging. Others add methionine because a panel reports a low value.

Methionine is essential.

Chronic inadequate protein or methionine intake can impair:

• protein synthesis;
• SAM supply;
• muscle maintenance;
• overall nutrition.

Severe restriction is not a benign methylation strategy.

Experimental methionine-restriction diets used in animal research are highly controlled and often reduce methionine by approximately 80 percent using purified amino-acid diets.

These models cannot be reproduced safely by simply removing protein-rich foods from an ordinary diet.

High protein intake does not automatically cause “overmethylation.” The liver normally increases methionine disposal when intake rises.

Problems may emerge when there is:

• an inherited disorder;
• severe liver dysfunction;
• unusual supplement dosing;
• a poorly balanced diet.

Symptom reactions alone do not demonstrate methionine accumulation.

A low plasma methionine result should also be interpreted cautiously.

Relevant factors include:

• recent intake;
• fasting;
• total protein status;
• malabsorption;
• catabolic illness;
• remethylation;
• analytical variability.

Adding isolated L-methionine without clarifying the context can worsen hypermethioninemia, alter sulfur metabolism, or produce side effects.

Folate and vitamin B12 support methionine synthase-dependent remethylation. Deficiency can raise homocysteine and reduce regeneration of methionine.

Severe functional vitamin B12 deficiency may be present even when serum vitamin B12 is difficult to interpret, so methylmalonic acid and clinical context can be useful.

Folate measurements also have limitations and differ between serum and red-cell assessment.

In a liver-related pattern, folate and vitamin B12 findings must be integrated rather than assumed.

Chronic liver disease can affect serum vitamin B12 through release and altered binding proteins, sometimes producing high serum values that do not simply represent high intake.

Alcohol exposure can impair folate status.
Supplement use can normalize serum concentrations without resolving all downstream issues.

The common error is to see high homocysteine and assume that methylfolate is the answer.

Other factors should be considered:

• kidney function;
• vitamin B12;
• vitamin B6;
• thyroid status;
• medication;
• smoking;
• alcohol;
• genetic disease.

The opposite error is to see low homocysteine and assume folate and vitamin B12 are excessive.
Low homocysteine can occur for several reasons and is not a validated marker of global overmethylation.

Vitamin B6 is required for cystathionine beta-synthase and cystathionine gamma-lyase.

Deficiency can limit transsulfuration and contribute to elevated homocysteine.

Excess supplemental vitamin B6, particularly prolonged high exposure, can cause neuropathy. A pathway diagram does not justify high-dose pyridoxal 5′-phosphate.

In chronic liver disease, vitamin B6 metabolism and nutritional status can be altered. Yet the direction of homocysteine change still depends on many factors.

Vitamin B6 should be viewed as one cofactor within a broader assessment, not as a universal correction for sulfur-flow concerns.

Because GNMT transfers a methyl group to glycine, people sometimes infer that glycine supplementation will “buffer excess methyl groups.”

The reaction is real, but the clinical inference is uncertain.

Relevant factors include:

• GNMT activity;
• SAM concentration;
• folate binding;
• hepatic expression;
• glycine availability.

Glycine also participates in:

• glutathione synthesis;
• collagen synthesis;
• heme synthesis;
• purine metabolism;
• bile-acid conjugation;
• neurotransmitter-related effects.

A calming or activating response to glycine cannot identify GNMT function.

In true GNMT deficiency, the problem is the enzyme, not simply a lack of glycine.

In common liver disease, altered GNMT expression may coexist with many other changes. Glycine may be nutritionally relevant, but it is not a functional test.

The kidney participates in homocysteine metabolism and expresses betaine-homocysteine methyltransferase.

Reduced kidney function can raise homocysteine and substantially alter:

• SAH;
• SAM;
• related one-carbon metabolites.

This can make a liver-centered interpretation misleading.

Creatinine, estimated glomerular filtration rate, cystatin C when appropriate, urinary albumin, and the overall renal context should be reviewed when SAM, SAH, or homocysteine are abnormal.

A low SAM/SAH ratio in chronic kidney disease may reflect renal retention and systemic metabolic changes rather than a primary hepatic deficit.

Hypothyroidism can raise homocysteine and contribute to dyslipidemia and steatosis.

Other conditions that can alter amino acids and liver markers include:

• hyperthyroidism;
• severe illness;
• inflammation;
• infection;
• cancer;
• catabolic states.

Medications can cause:

• steatosis;
• cholestasis;
• hepatocellular injury;
• changes in folate and vitamin status.

A complete interpretation therefore includes:

• prescription medication;
• over-the-counter products;
• alcohol;
• supplements;
• hormonal therapy;
• recent illness.

“Liver support” products are not automatically harmless. Multi-ingredient supplements can cause liver injury and obscure the picture.

Estrogen upregulates phosphatidylethanolamine N-methyltransferase expression.

This helps explain why premenopausal women may have greater endogenous phosphatidylcholine synthesis and why choline requirements can change after menopause.

Human depletion studies found differences in susceptibility by sex and menopausal status.

This does not mean that every postmenopausal woman with fatty liver has a PEMT problem.

It does mean that the following can interact:

• age;
• hormonal state;
• dietary choline;
• metabolic risk;
• genetics.

This is a more defensible interpretation than treating one PEMT variant as destiny.

Before attributing a result to hepatic methionine/SAM dysregulation, ask:

1. Is there established liver disease, and how was it assessed?
2. Is there metabolic risk, including insulin resistance, diabetes, dyslipidemia, or central adiposity?
3. What is the alcohol exposure?
4. Is protein intake adequate, excessive, or highly restrictive?
5. Is choline intake plausibly low?
6. Are folate, vitamin B12, and vitamin B6 status reasonably assessed?
7. Is kidney function normal?
8. Are medications or supplements affecting the liver or one-carbon metabolism?
9. Was the sample fasting and handled correctly?
10. Is the finding persistent?
11. Does the magnitude suggest a rare inherited disorder?

Genetics can clarify a pathway, but it can also create false certainty.

The same report may list hundreds of common variants, label several enzymes as “slow,” and imply a degree of functional impairment that has never been measured.

This block separates three different kinds of genetic information:

1. common variants that may modestly modify risk or nutrient requirements;
2. rare pathogenic variants that cause recognized inherited metabolic disease;
3. somatic or expression changes that arise within chronic liver disease or cancer.

These categories should not be mixed.

Methionine adenosyltransferase 1A (MAT1A) encodes the catalytic subunit that forms hepatic methionine adenosyltransferase I and methionine adenosyltransferase III.

Pathogenic MAT1A variants can cause methionine adenosyltransferase I/III deficiency, the most common cause of persistent isolated hypermethioninemia detected through newborn screening in many programs.

The phenotype is variable.

Some dominant heterozygous variants produce mild persistent hypermethioninemia with no apparent clinical consequences.

Biallelic variants can produce much higher methionine and may be associated with neurologic findings, developmental concerns, demyelination, or unusual odor.

Not every person with MAT1A-related hypermethioninemia needs the same intervention.

Consensus recommendations use methionine concentration, genotype, symptoms, and neurologic assessment to guide management.

A common consumer variant in MAT1A is not equivalent to methionine adenosyltransferase I/III deficiency.

Diagnosis requires a coherent biochemical pattern and pathogenic variant interpretation.

The key biochemical question is not merely whether methionine is high, but whether total homocysteine is elevated and what S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) show.

Glycine N-methyltransferase (GNMT) buffers hepatic SAM.

Pathogenic biallelic GNMT variants cause a very rare disorder characterized by persistent hypermethioninemia, markedly elevated SAM, and liver findings such as hepatomegaly or elevated aminotransferases.

Reported patients have often had relatively mild clinical presentations compared with the dramatic biochemical values, although long-term risk remains an important concern.

Common GNMT variants have been studied for possible effects on enzyme function, cancer risk, and one-carbon metabolism.

These associations do not justify diagnosing GNMT deficiency from a consumer report. True deficiency is identified through biochemical and molecular evaluation.

The distinction is clinically important because the intuitive response to high methionine may be to add methyl donors or to assume poor methionine conversion. In GNMT deficiency, SAM is already very high.

The pathway problem is not a lack of methyl supply.

The AHCY gene encodes S-adenosylhomocysteine hydrolase.

Pathogenic biallelic variants cause S-adenosylhomocysteine hydrolase deficiency, a rare multisystem disorder.

Reported features include:

• hypotonia;
• developmental delay;
• myopathy;
• elevated aminotransferases;
• coagulopathy;
• liver disease;
• neurologic involvement.

Biochemically, SAH is markedly elevated, SAM is often elevated, and methionine may be elevated.
The disorder demonstrates product inhibition in a direct human form.

SAH accumulation can impair methylation even when SAM is abundant.

Published cases have used methionine restriction and other individualized management under specialist care, but evidence is limited because the disorder is extremely rare.

A mild change in a common AHCY single-nucleotide polymorphism does not imply AHCY deficiency. The clinical disorder has a distinctive biochemical severity and requires specialist testing.

Adenosine kinase, encoded by ADK, phosphorylates adenosine and helps maintain the gradient that favors SAH hydrolysis.

Adenosine kinase deficiency can disrupt the methionine cycle, causing:

• hypermethioninemia;
• elevated SAM and SAH;
• liver dysfunction;
• hypoglycemia;
• hypotonia;
• developmental delay;
• characteristic neurologic or dysmorphic findings.

Published cases show that methionine restriction can improve biochemical abnormalities and some clinical features, but responses are variable and treatment is specialist-directed.

The disorder highlights a principle that is often missed in simplified methylation diagrams: SAH clearance depends not only on homocysteine but also on adenosine metabolism.

Cystathionine beta-synthase (CBS) deficiency is classically associated with elevated total homocysteine and methionine.

Because untreated CBS deficiency carries thromboembolic, ocular, skeletal, and neurologic risks, it is an important early exclusion when methionine is persistently high.

The presence of high methionine should therefore prompt examination of total homocysteine before the result is framed as a liver or SAM-handling issue.

Isolated hypermethioninemia and hypermethioninemia with severe hyperhomocysteinemia belong to different diagnostic pathways.

Common CBS variants reported by consumer platforms do not diagnose “CBS upregulation.”

The popular interpretation that a common variant causes constitutively accelerated transsulfuration and universally low homocysteine is not supported as a clinical diagnosis.

Betaine-homocysteine methyltransferase (BHMT) is highly expressed in the liver and kidney.

Common BHMT variants have been studied in relation to homocysteine, choline metabolism, pregnancy, cardiovascular risk, and other outcomes.

Effects are generally modest and context-dependent.

There is no routine clinical diagnosis of “slow BHMT” based on one common variant. A person with high homocysteine may have:

• limited folate-dependent remethylation;
• kidney dysfunction;
• vitamin deficiency;
• thyroid disease;
• medication effects;
• other causes.

Response to trimethylglycine does not prove a BHMT genotype effect.

Rare severe BHMT deficiency has not emerged as a common human metabolic diagnosis in the way MAT1A, GNMT, AHCY, and ADK disorders have. This should temper claims made from common variants.

Phosphatidylethanolamine N-methyltransferase (PEMT) is central to hepatic phosphatidylcholine synthesis.

Common PEMT variants have been associated in some studies with susceptibility to choline deficiency, fatty liver, or altered choline requirements.

The frequently discussed rs12325817 variant has been examined in controlled choline-depletion research, and rs7946 has been studied in several metabolic contexts.

The strength and direction of associations differ by:

• population;
• sex;
• hormonal status;
• dietary intake;
• study design.

A common PEMT variant is best viewed as a possible modifier. It does not establish fatty liver, prove impaired very-low-density lipoprotein export, or determine a supplement dose.

A more responsible interpretation is:

This variant may modestly alter susceptibility within a context that includes choline intake, estrogen status, metabolic health, liver disease, and other genes.

Methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), and methionine synthase reductase (MTRR) influence folate- and vitamin B12-dependent remethylation.

Common MTHFR C677T and A1298C variants can modify enzyme activity, particularly when folate status is low. They are relevant to homocysteine but do not diagnose hepatic SAM dysregulation.

A person can have a common MTHFR variant and normal homocysteine. A person without the variant can have high homocysteine due to:

• kidney disease;
• vitamin deficiency;
• hypothyroidism;
• medication;
• smoking;
• other factors.

Genetic interpretation should not replace biochemical assessment.

The liver context matters because chronic liver disease can alter folate handling, vitamin B12 markers, and enzyme expression. Yet the existence of a liver condition does not make a common MTHFR variant the primary cause.

Methionine adenosyltransferase 2A (MAT2A) and methionine adenosyltransferase 2B (MAT2B) are important in proliferating liver cells, injury, fibrosis, and cancer biology.

Most discussion in this area concerns gene expression, regulation, and somatic disease processes rather than common inherited variants that can be used for consumer recommendations.

A report that lists MAT2A or MAT2B single-nucleotide polymorphisms should be interpreted cautiously.

The clinically important MAT1A-to-MAT2A/MAT2B switch is largely an expression and disease-state phenomenon, not something established by a simple consumer genotype label.

Chronic liver injury and cancer can change gene expression and epigenetic regulation within hepatocytes.

MAT1A may be silenced, MAT2A induced, GNMT reduced, and deoxyribonucleic acid methylation remodeled.

These somatic changes occur in diseased tissue and are not equivalent to inherited germline variants found in saliva.

This distinction matters because articles on hepatocellular carcinoma are sometimes used to interpret consumer genetic data.

A molecular pathway that is active in tumor tissue does not mean that a person with a common germline variant has the same cellular state.

Consensus recommendations propose a structured approach to persistent hypermethioninemia.

The exact pathway depends on age and clinical presentation, but commonly includes:

• repeat plasma amino acids under appropriate conditions;
• total homocysteine;
• SAM and SAH when available through specialized laboratories;
• liver tests and clinical examination;
• assessment of neurologic, developmental, muscular, and coagulation findings;
• exclusion of nutritional and liver-related causes;
• molecular testing targeted to the biochemical pattern.

The biochemical pattern helps prioritize genes.

High methionine with very high homocysteine points toward CBS-related disease.

High methionine with low or normal homocysteine raises other possibilities.

Very high SAM suggests GNMT-related disease.

Very high SAH suggests AHCY or adenosine-related disturbance.

MAT I/III deficiency detected through screening

Published series describe infants and children identified because newborn screening showed elevated methionine.

Some had dominant MAT1A variants and remained clinically well, while others with biallelic variants had higher methionine and neurologic concerns.

These cases demonstrate why persistence, genotype, concentration, and symptoms matter more than the label “high methionine.”

GNMT deficiency

Published GNMT-deficient patients had striking biochemical findings, including marked hypermethioninemia and very high SAM, with liver enlargement or enzyme elevation.

The cases show that high SAM can coexist with liver pathology and that the buffering role of GNMT is clinically real.

S-adenosylhomocysteine hydrolase deficiency

Case reports and series describe children and adults with:

• myopathy;
• hypotonia;
• developmental issues;
• elevated aminotransferases;
• coagulation abnormalities;
• marked SAH elevation.

Some reports describe dietary methionine restriction with biochemical improvement. These are specialist metabolic cases, not models for self-directed restriction.

Adenosine kinase deficiency

Published cases include:

• neonatal or childhood hypoglycemia;
• hypotonia;
• liver dysfunction;
• developmental delay;
• hypermethioninemia.

Methionine restriction has been associated with biochemical improvement in some patients, again under specialist supervision.

This is the block in which most interpretive errors occur.

A laboratory result feels concrete, but a concrete number can still be nonspecific.

The aim is not to collect the largest possible panel.

It is to understand what each marker measures, what it does not measure, and which combinations deserve a different level of attention.

Plasma methionine is usually measured as part of a plasma amino-acid profile.

It reflects the circulating pool at the time of collection.

It is influenced by:

• recent food intake;
• fasting duration;
• protein turnover;
• hepatic uptake;
• conversion to SAM;
• remethylation;
• transsulfuration;
• age;
• illness;
• inherited disorders.

What a high value can mean

A high methionine result can occur with:

• recent methionine or protein intake;
• MAT1A-related methionine adenosyltransferase I/III deficiency;
• GNMT deficiency;
• AHCY deficiency;
• adenosine kinase deficiency;
• CBS deficiency, usually with high total homocysteine;
• severe liver dysfunction;
• parenteral nutrition or specialized formulas;
• transient neonatal or illness-related changes;
• laboratory or pre-analytical factors.

The magnitude matters.

A small elevation on one nonfasting sample is not interpreted in the same way as persistent marked hypermethioninemia on repeated plasma amino-acid testing.

What a low value can mean

A low methionine result can occur with:

• low protein or methionine intake;
• malabsorption or inadequate total nutrition;
• catabolic illness;
• impaired remethylation;
• increased utilization or altered amino-acid balance;
• sample timing and laboratory variation.

A low result does not prove that the liver cannot produce SAM.

Direct SAM measurement, accompanying amino acids, nutritional status, homocysteine, vitamin status, and clinical context are needed before locating the problem.

The common misunderstanding

“High methionine means I am eating too much protein” and “low methionine means I should take L-methionine” are both premature conclusions.

Methionine is a node, not a diagnosis.

S-adenosylmethionine can be measured in plasma, serum, whole blood, erythrocytes, cells, or tissue, depending on the research or specialist method.

These compartments are not interchangeable. SAM is labile, and analytical methods vary.

What a low value may suggest

A low SAM concentration may be consistent with:

• reduced methionine availability;
• impaired methionine-to-SAM conversion;
• high utilization relative to production;
• advanced liver dysfunction;
• specimen or analytical problems.

It does not reveal which methylation reactions are affected.

It also does not automatically justify SAMe supplementation.

What a high value may suggest

A high SAM concentration may occur with:

• GNMT deficiency or reduced buffering;
• AHCY or adenosine-related disorders;
• renal dysfunction;
• exogenous SAMe use;
• altered tissue export or distribution;
• selected metabolic and liver-disease contexts.

High SAM does not equal globally high methylation.

If SAH is also high, methyltransferases may still be inhibited. If GNMT is deficient, SAM may accumulate because it is not being buffered normally.

The common misunderstanding

People often interpret SAM as if it were a fuel-gauge reading.

In reality, it is a dynamic metabolite distributed among many competing reactions. A pool size does not
directly measure flux.

S-adenosylhomocysteine is the product of SAM-dependent methyl transfer and an inhibitor of many methyltransferases.

It is particularly sensitive to disturbances in homocysteine, adenosine, and renal metabolism.

What an elevated value may suggest

• increased methyltransferase product load;
• impaired SAH hydrolysis or downstream removal;
• renal dysfunction;
• AHCY deficiency;
• adenosine kinase deficiency;
• altered liver metabolism;
• systemic metabolic or vascular disease.

An elevated value does not, by itself, identify the liver as the source.

Kidney function and the analytical method are essential parts of interpretation.

Why SAH can be more informative than homocysteine

Homocysteine is downstream of SAH and is rapidly routed into remethylation or transsulfuration.
SAH more directly reflects product inhibition of methyltransferases. In some research contexts, SAH correlates more strongly than homocysteine with impaired methylation potential.

However, its measurement is less standardized and less widely available.

The SAM/SAH ratio is frequently described as an index of methylation potential.

This description is biochemically reasonable, but several caveats are necessary.

A ratio is not a diagnosis

There is no universal cut-off that establishes hepatic methylation failure across all laboratories and populations.

Different studies use different:

• specimens;
• units;
• methods;
• disease groups.

A result must be interpreted against the laboratory’s validated reference interval.

Absolute values matter

A ratio of 3 can arise from:

• low SAM and modest SAH;
• normal SAM and high SAH;
• very high concentrations of both.

These profiles have different implications.

Compartment matters

Plasma ratios do not necessarily represent:

• hepatocyte cytosol;
• hepatocyte nuclei;
• mitochondria;
• other tissues.

Tissue SAM and plasma SAM can move differently in disease.

Timing and handling matter

SAM and SAH require:

• careful collection;
• rapid processing;
• appropriate temperature control;
• validated storage.

Delays can distort results.

A commercial panel should disclose the specimen, method, reference interval, and handling requirements.

The common misunderstanding

A low ratio is often treated as a signal to add methyl donors.

If the ratio is low because SAH is high, increasing methyl supply may not address the dominant constraint.

Total homocysteine is the most commonly available marker in this network.

It includes several forms of homocysteine in plasma and is influenced by:

• remethylation;
• transsulfuration;
• kidney function;
• age;
• genetics;
• vitamin status;
• thyroid function;
• smoking;
• alcohol;
• medication;
• illness.

High homocysteine

Common contributors include:

• folate deficiency;
• vitamin B12 deficiency;
• vitamin B6 deficiency;
• kidney dysfunction;
• hypothyroidism;
• smoking;
• selected medications;
• aging;
• common MTHFR variation in a low-folate context;
• inherited disorders such as CBS deficiency or severe remethylation disorders.

Liver disease can contribute, but high homocysteine is not liver-specific.

Low homocysteine

Low total homocysteine is less well standardized as a clinical problem.

It can occur with:

• low methionine intake;
• low protein status;
• pregnancy;
• high remethylation support;
• high transsulfuration demand;
• certain illnesses;
• analytical variation.

It does not establish “overmethylation” or “CBS upregulation.”

Why normal homocysteine can be misleading

A normal value does not prove that SAM and SAH are normal.

Homocysteine is a branch point and can be maintained within range despite changes upstream. It also cannot exclude fatty liver, fibrosis, or altered hepatic gene expression.

Cystathionine can provide information about transsulfuration and vitamin B6-related metabolism.

Cysteine and cystine reflect sulfur amino-acid status and redox conditions, but they are sensitive to handling and oxidation.

A pattern of high methionine, low homocystine, and low cystine may prompt questions about transsulfuration, but it does not establish a diagnosis.

The terms homocysteine and homocystine are also sometimes confused. Clinical total homocysteine is not the same measurement as homocystine on an amino-acid panel.

Interpretation should clarify:

• what analyte was actually measured;
• whether the sample was plasma or urine;
• whether the concentration was total or free;
• fasting status;
• sample oxidation and processing;
• vitamin B6 status;
• kidney and liver context.

Choline can be used for:

• phosphatidylcholine synthesis;
• acetylcholine synthesis;
• oxidation to betaine.

Betaine supports BHMT-dependent remethylation, producing methionine and dimethylglycine.

Potentially informative relationships

• Low choline intake plus liver fat may raise concern about phosphatidylcholine supply.
• Low betaine with high homocysteine may suggest limited substrate for BHMT, but is not diagnostic.
• Increased dimethylglycine after trimethylglycine can show that betaine is being metabolized, but does not quantify liver benefit.
• High dimethylglycine can reflect intake, BHMT flux, kidney function, or other factors.

Commercial metabolomic panels sometimes assign pathway scores from these metabolites. Such scores are hypotheses, not direct measurements of enzyme activity.

Serum folate reflects recent intake more than long-term tissue status. Red-cell folate reflects longer-term exposure but has its own methodological issues.

5-methyltetrahydrofolate is the form used by methionine synthase, but routine testing rarely maps intracellular folate distribution.

A normal or high serum folate does not guarantee normal intracellular vitamin B12-dependent remethylation.

High supplemental folate can coexist with vitamin B12 deficiency. Conversely, a common MTHFR variant does not mean that methylfolate is always required.

Serum vitamin B12 can be low, normal, or high for multiple reasons.

Methylmalonic acid and holotranscobalamin can add information, but methylmalonic acid rises with kidney dysfunction.

Chronic liver disease can elevate serum vitamin B12 through altered storage, release, and binding proteins.

The useful question is not simply:

“Is vitamin B12 high?”

It is whether the overall evidence supports adequate cellular cobalamin function and whether the result is distorted by liver or kidney disease.

Alanine aminotransferase and aspartate aminotransferase

Alanine aminotransferase and aspartate aminotransferase reflect hepatocellular injury, not the liver’s complete functional capacity.

Normal values do not exclude steatosis or fibrosis. Aspartate aminotransferase also comes from muscle and other tissues.

Gamma-glutamyl transferase

Gamma-glutamyl transferase can rise with:

• cholestasis;
• alcohol exposure;
• metabolic liver disease;
• medication.

It is not a direct measure of glutathione sufficiency, despite its connection to glutathione metabolism.

Alkaline phosphatase and bilirubin

These markers help identify cholestatic or biliary patterns. Their interpretation belongs to established liver evaluation, not to a methylation score.

Albumin and coagulation

Albumin and the international normalized ratio contribute information about synthetic function, especially in advanced disease. They may remain normal in early steatosis.

Platelets and fibrosis scores

Platelet count, age, alanine aminotransferase, and aspartate aminotransferase are used in non-invasive fibrosis tools such as the Fibrosis-4 Index.

Fibrosis risk is often more clinically important than a speculative methylation label.

Ultrasound can detect steatosis but has limited sensitivity for mild fat and does not accurately stage fibrosis.

Controlled attenuation parameter, vibration-controlled transient elastography, magnetic resonance-based methods, and other tools can provide additional information. Liver biopsy is reserved for selected situations.

A finding of fatty liver creates a relevant context for methionine and choline metabolism, but it does not establish the direction of SAM change.

Imaging should be interpreted within hepatology guidance.

Creatinine, estimated glomerular filtration rate, cystatin C, urinary albumin, and the overall renal picture are important when homocysteine, SAM, or SAH are abnormal.

Reduced renal function can increase homocysteine and SAH and may change the SAM/SAH ratio.

A hepatic interpretation that omits kidney function is incomplete.

The following combinations are not diagnoses. They are questions to investigate.

High methionine + high total homocysteine

Consider:

• CBS deficiency, especially if marked or persistent;
• severe vitamin-related or remethylation abnormalities with an unusual context;
• kidney dysfunction;
• liver disease;
• intake or medication effects.

Priority: confirm the values and evaluate through an appropriate clinical pathway rather than adding methyl donors.

High methionine + normal or low total homocysteine

Consider:

• MAT1A deficiency;
• GNMT deficiency;
• AHCY deficiency;
• adenosine kinase deficiency;
• liver dysfunction;
• recent methionine intake;
• isolated laboratory variation.

SAM and SAH can be especially informative in the rare-disorder differential.

High methionine + low SAM

This pattern could be consistent with constrained methionine-to-SAM conversion, but confirmation and context are essential.

Consider:

• MAT1A-related disease;
• acquired reduction in methionine adenosyltransferase activity;
• sample differences;
• the fact that plasma values do not directly measure hepatocyte flux.

High methionine + very high SAM + relatively normal SAH

This is a classic pattern raising concern for GNMT deficiency in the appropriate setting.

It is not a common functional-medicine phenotype.

High methionine + high SAM + very high SAH

Consider:

• AHCY deficiency;
• adenosine kinase deficiency;
• kidney dysfunction;
• severe systemic disease;
• other causes.

The magnitude and clinical context determine urgency.

Low methionine + low SAM

Consider:

• inadequate intake;
• malabsorption;
• catabolism;
• impaired remethylation;
• reduced methionine adenosyltransferase activity;
• high demand;
• analytical issues.

Do not assume that isolated methionine supplementation is the correct response.

Normal methionine + low SAM/SAH ratio

Look at the absolute SAM and SAH values.

Elevated SAH due to kidney dysfunction or impaired clearance may be more important than methionine supply.

Elevated liver enzymes + normal methionine and homocysteine

This does not exclude altered hepatic SAM homeostasis, but the immediate priority is the established differential for liver injury.

Methylation markers are not required to investigate common liver disease.

Fatty liver + low choline intake

This is a plausible nutrient context, especially when intake is clearly inadequate or when a person has been on parenteral nutrition or a highly restrictive diet.

It does not prove that choline is the sole cause of fatty liver.

Fatty liver + PEMT variant

Treat the variant as a modifier.

Assess:

• dietary choline;
• metabolic risk;
• sex and hormonal state;
• alcohol;
• medication;
• fibrosis risk.

Do not infer a dose from genotype alone.

Methionine-to-SAM Supply Limitation

This narrower pattern focuses on insufficient SAM production from methionine.

Hepatic dysregulation overlaps when MAT1A activity or liver function is the proposed cause. The hepatic pattern is broader because it also includes high SAM, SAH accumulation, altered buffering, and secondary liver contexts.

Key distinction:

Supply limitation asks whether SAM production is inadequate. Hepatic homeostasis asks how the liver is regulating the entire methionine-SAM-SAH system.

SAH-Driven Low Methylation Potential

This pattern focuses on SAH accumulation and methyltransferase inhibition.

It can occur because of:

• kidney dysfunction;
• altered adenosine metabolism;
• AHCY-related disease;
• high product load;
• liver-related changes.

Key distinction:

SAH-driven limitation can be hepatic, renal, inherited, or systemic. The liver pattern is only one possible context.

High SAM-Derived Methyl-Group Demand Pressure

This pattern focuses on high demand for SAM-dependent reactions, including phosphatidylcholine and creatine synthesis.

The hepatic chapter explains why PEMT, GNMT, lipid export, and liver disease can modify that demand.

Key distinction:

High demand is about consumption relative to supply. Hepatic dysregulation can involve high demand, but it can also involve impaired production or impaired use.

Choline-Betaine-Dependent Remethylation Limitation

This pattern focuses on the choline-betaine-BHMT route that remethylates homocysteine to methionine.

The hepatic chapter includes BHMT because the enzyme is highly expressed in the liver and because liver injury can alter its expression.

Key distinction:

BHMT limitation is one branch. Hepatic homeostasis includes SAM synthesis, SAH clearance, GNMT buffering, and PEMT demand as well.

Folate-Limited and Vitamin B12-Dependent Remethylation Patterns

These patterns focus on methionine synthase-dependent recycling of homocysteine.

They can secondarily affect methionine and SAM, but they are not inherently liver-specific.

Key distinction:

A folate or vitamin B12 problem can alter hepatic methionine supply without primary liver dysfunction.

B6-Dependent Transsulfuration Limitation

This pattern focuses on conversion of homocysteine through cystathionine toward cysteine.

It can raise homocysteine and alter glutathione-related supply.

Key distinction:

Transsulfuration is downstream of homocysteine. The hepatic pattern begins earlier and includes both remethylation and SAM regulation.

Accelerated Transsulfuration or Low-Homocysteine Sulfur-Flux Patterns

These interpretations attempt to explain low homocysteine and sulfur-related findings through increased transsulfuration.

Evidence is often indirect.

Key distinction:

Low homocysteine alone does not establish accelerated hepatic transsulfuration. Dietary intake, remethylation, pregnancy, illness, and analytical factors must be considered.

Renal Retention of One-Carbon Metabolites

Renal dysfunction can raise homocysteine, SAH, SAM, and related metabolites, producing a pattern that looks like impaired methylation or liver dysfunction.

Key distinction:

Always review kidney function before assigning abnormal SAM, SAH, or homocysteine to the liver.

Stage 1. Verify the finding

• Was the test appropriate for the question?
• Was the sample fasting if required?
• Was supplementation stopped or documented?
• Was handling adequate?
• Is the result reproducible?
• Are the units and reference interval clear?

Stage 2. Identify the dominant abnormality

• Is methionine high or low?
• Is SAM high or low?
• Is SAH high?
• Is total homocysteine high or low?
• Are liver injury, cholestatic, or synthetic markers abnormal?
• Is kidney function abnormal?

Stage 3. Locate the likely node

• Methionine supply?
• Methionine adenosyltransferase-dependent SAM production?
• Methyltransferase demand?
• GNMT buffering?
• SAH hydrolysis?
• Homocysteine remethylation?
• Transsulfuration?
• Phosphatidylcholine demand?
• Renal retention?

Stage 4. Separate common from rare explanations

Common metabolic liver disease, nutritional factors, kidney function, medication, alcohol, and vitamin status should be considered.

The following raise the priority of rare inherited disorders:

• marked persistent abnormalities;
• childhood onset;
• neurologic or muscular findings;
• coagulopathy;
• hypoglycemia;
• very high SAM or SAH.

Stage 5. Avoid treatment-by-marker

A marker identifies a question, not automatically an intervention.

• High homocysteine does not always mean methylfolate.
• Low SAM does not always mean SAMe.
• High methionine does not always mean protein restriction.
• A low SAM/SAH ratio does not always mean more methyl donors.

This block addresses the questions that most often lead people into the topic.

It does not provide a supplement protocol.

Its purpose is to explain why a response can be real without proving the proposed mechanism.

A response to food or a supplement is shaped by dose, timing, formulation, baseline nutrient status, medications, sleep, gastrointestinal absorption, kidney function, liver disease, genetic disease, expectation, and simultaneous changes.

The same substance can help at one dose and cause problems at another. It can also produce different effects on different days.

S-adenosylmethionine is sold as SAMe.

Oral SAMe has been studied in depression, osteoarthritis, cholestatic conditions, and liver disease. It is pharmacologically active and is not simply a nutritional equivalent of eating methionine.

Why it may help

Possible reasons include:

• bypassing a constrained methionine-to-SAM step;
• influencing monoamine-related methylation and neurotransmitter metabolism;
• supporting selected phospholipid or glutathione-related pathways;
• pharmacologic effects unrelated to a documented deficiency;
• correction of a true low-SAM state in a specific disease context.

Improved energy, mood, motivation, or cognition does not locate the effect in the liver.

SAMe acts in multiple tissues.

Why it may cause activation, anxiety, or insomnia

Possible contributors include:

• dose too high for the individual;
• rapid changes in neurotransmitter-related pathways;
• bipolar-spectrum vulnerability or mood activation;
• interaction with antidepressants or other serotonergic agents;
• timing late in the day;
• gastrointestinal effects or sleep disruption;
• downstream demand for cofactors and substrates;
• expectation and concurrent changes.

The reaction is not a validated test for “overmethylation.”

It is a reason to reconsider dose, safety, interactions, and whether the compound is appropriate.

Why the effect may fade

An initial response can diminish because of adaptation, changing expectations, altered sleep, progression of the underlying condition, inadequate adherence, formulation differences, or because the original effect was not caused by a persistent SAM deficiency. A fading response does not prove depletion of another cofactor.

Why stopping can feel difficult

Some users report a return of low mood or energy after stopping. This may represent recurrence of the underlying symptoms, an adjustment effect, or expectation. Evidence for a defined SAMe withdrawal syndrome is limited. Persistent or severe changes should be evaluated rather than managed through escalating self-experimentation.

Medication safety

SAMe can interact with serotonergic medication and may contribute to serotonin-related adverse effects. It may also provoke mania or hypomania in susceptible individuals. Pregnancy, bipolar disorder, significant medical illness, and complex medication regimens require professional guidance.

Liver evidence

The liver rationale is strong, but clinical trials are mixed. Some studies suggest biochemical or symptom improvement in selected cholestatic or chronic liver conditions. Trials in alcohol-related liver disease have not produced consistently positive outcomes. SAMe should not be presented as a general treatment for fatty liver or elevated liver enzymes.

L-methionine is an essential amino acid, but isolated supplementation changes the pathway differently from SAMe.

Why someone considers it

• low methionine on an amino-acid panel;
• low-protein or plant-based diet concerns;
• a theory that SAM production is substrate-limited;
• attempts to raise homocysteine;
• mood or detoxification claims.

What it can and cannot show

If methionine improves a symptom, that may indicate substrate responsiveness, but it does not prove hepatic MAT activity is normal or abnormal. If it worsens anxiety, insomnia, nausea, or sulfur-related symptoms, the response does not diagnose high SAM or CBS upregulation.

Main caution

Methionine should not be added casually when methionine is already high, when the cause of a low value is unknown, or when an inherited disorder is possible. Marked hypermethioninemia can have neurologic consequences in selected disorders. The essential status of methionine does not make high-dose isolated supplementation universally safe.

People sometimes report feeling worse after high-protein meals and attribute the reaction to methionine or slow COMT.

Protein meals also change blood glucose, insulin, glucagon, gut hormones, ammonia production, large neutral amino-acid competition, gastrointestinal load, and hydration. Protein powders may include sweeteners, additives, dairy proteins, histamine-related ingredients, or contaminants.

What a response does not prove

• that methionine is accumulating;
• that COMT is overwhelmed by methyl groups;
• that the liver cannot process protein;
• that a low-protein diet is required;
• that the person has an inherited methylation disorder.

What to investigate instead

• total amount and meal size;
• source of protein;
• carbohydrate and fat context;
• digestive symptoms;
• kidney and liver status;
• ammonia-related concerns in advanced liver disease;
• overall energy intake;
• actual plasma amino-acid results if clinically indicated.

In advanced cirrhosis, protein recommendations require individualized clinical nutrition. Older advice to broadly restrict protein has largely been replaced by efforts to prevent malnutrition and sarcopenia, except in selected circumstances. Self-imposed restriction can be harmful.

Choline supplements come in several forms, including choline salts, phosphatidylcholine, citicoline, and alpha-glycerylphosphorylcholine. These forms differ in pharmacology and cannot be treated as interchangeable.

Why choline may help

• correction of low dietary intake;
• support of phosphatidylcholine synthesis;
• support of acetylcholine-related function;
• increased betaine production through oxidation;
• selected parenteral-nutrition or deficiency contexts.

Why choline may cause adverse effects

• gastrointestinal discomfort;
• fishy body odor at high intake due to trimethylamine;
• sweating or salivation;
• headache or mood changes;
• cholinergic effects depending on form;
• interaction with gut microbial metabolism;
• dose or formulation intolerance.

A cognitive response to citicoline or alpha-glycerylphosphorylcholine does not demonstrate that hepatic phosphatidylcholine synthesis was deficient. These compounds have central nervous system effects.

Fatty liver and choline

Human depletion studies show that choline deficiency can cause fatty liver in susceptible people and that repletion can reverse the induced abnormality. This is strong evidence for deficiency-related steatosis. It is not evidence that most metabolic dysfunction-associated steatotic liver disease can be treated with choline alone.

Genotype-guided dosing

No common phosphatidylethanolamine N-methyltransferase (PEMT) variant currently provides a validated personal dose. Intake assessment, food sources, hormonal state, tolerability, metabolic risk, and liver evaluation are more informative than a single variant.

Phosphatidylcholine directly supplies a major phospholipid and differs from free choline. It is used in cell membranes, bile, and lipoproteins.

Oral phosphatidylcholine is digested and remodeled, so it does not simply travel intact to a deficient hepatic pool.

Improvement in digestive tolerance or cognition after phosphatidylcholine does not prove PEMT insufficiency.

Lack of response does not prove adequate choline status. Products vary in purity and phospholipid composition.

Trimethylglycine is betaine. Through betaine-homocysteine methyltransferase (BHMT), it donates a methyl group to homocysteine, producing methionine and dimethylglycine.

It is sometimes used to lower homocysteine and is an established therapy component in selected inherited homocystinurias under medical supervision.

Why responses vary

• baseline homocysteine may be low, normal, or high;
• BHMT activity and liver expression vary;
• folate-dependent remethylation may be adequate or constrained;
• methionine and SAM may already be high;
• dose can affect gastrointestinal tolerance;
• betaine can influence osmolyte balance and lipid metabolism;
• concurrent methylfolate, vitamin B12, choline, and SAMe alter the context.

Why TMG can feel stimulating or sedating

The subjective effect may involve downstream methionine and SAM, changes in homocysteine, osmolyte effects, other supplements, sleep, or expectation. There is no validated rule that stimulation equals overmethylation and sedation equals undermethylation.

The important caution

Lowering homocysteine is not the only outcome. Betaine can raise methionine, which matters in certain inherited disorders. Treatment of homocystinuria uses monitoring and diagnosis, not indiscriminate dosing.

Methylfolate can support methionine synthase-dependent remethylation when folate supply or methylenetetrahydrofolate reductase-related conversion is limiting. It can also produce strong subjective effects in some people.

Commonly reported pattern

A person feels clearer or more energetic for several days, then develops anxiety, insomnia, headache, irritability, or a “crash.” Several explanations are possible:

• dose exceeds current tolerance;
• vitamin B12 status is inadequate;
• the original response was pharmacologic rather than correction of deficiency;
• sleep loss accumulates;
• other supplements create combined stimulation;
• an unrelated condition is fluctuating;
• expectation amplifies interpretation.

The reaction does not prove a liver bottleneck or the need to add every downstream cofactor.

Liver context

Chronic liver disease can alter folate status, but methylfolate is not a treatment for liver disease. High folate intake can mask hematologic signs of vitamin B12 deficiency, so vitamin B12 context matters.

Methylcobalamin provides a cofactor form used by methionine synthase. Adenosylcobalamin supports methylmalonyl-coenzyme A mutase.

Hydroxocobalamin can be converted to active forms and is used in several clinical contexts.

A response to one form does not reveal a universal “COMT type.”

High serum vitamin B12 after supplementation is expected and does not measure intracellular methylation.

Unexpectedly high serum vitamin B12 without supplementation can occur in liver disease, hematologic disease, kidney disease, or other conditions and should not be dismissed as “excellent status.”

Glycine is a substrate for glycine N-methyltransferase (GNMT) and glutathione synthesis and participates in many other pathways.

Why people use it

• to support sleep;
• to buffer perceived excess methyl groups;
• to support glutathione;
• to balance high methionine intake;
• to support collagen.

Why the interpretation is difficult

Glycine can have inhibitory neurotransmitter effects in some regions and excitatory co-agonist effects at N-methyl-D-aspartate receptors in others.

It also affects metabolism and temperature regulation. A calming response does not prove excess SAM, and an activating response does not prove GNMT dysfunction.

In true GNMT deficiency, adding glycine cannot replace the missing enzyme activity. In common metabolic contexts, the effect of glycine on hepatic SAM buffering in humans is not established as a diagnostic intervention.

Creatine may reduce endogenous guanidinoacetate methylation and thereby spare SAM-dependent methyl demand.

It also directly supports muscle phosphocreatine and can affect strength, cognition, and water retention.

A beneficial response may arise from muscle or brain energy effects rather than methyl-group sparing.

Irritability, gastrointestinal symptoms, or sleep changes are not specific to methylation. Kidney function and the interpretation of creatinine should be considered.

N-acetylcysteine supplies cysteine and has antioxidant and mucolytic effects. It is used medically in acetaminophen toxicity and other selected settings.

Why it enters methylation discussions

It connects to cysteine and glutathione downstream of transsulfuration. People may use it when they believe homocysteine is being diverted too slowly or when oxidative stress is high.

Why responses vary

N-acetylcysteine can affect glutamate-related signaling, histamine-related symptoms, gastrointestinal function, and redox state. A paradoxical reaction does not prove sulfur intolerance or hepatic transsulfuration overload.

In acute or chronic liver concerns, N-acetylcysteine should not be used as a substitute for identifying the cause of injury.

Niacin metabolism can use methyl groups, and niacin is sometimes recommended online to stop methyl-donor reactions.

This is an oversimplified and potentially unsafe practice.

Niacin has dose-dependent effects on flushing, glucose, uric acid, and the liver. Sustained-release high-dose products can cause hepatotoxicity.

Using niacin as an antidote to an undefined “overmethylation” state can add liver risk to an already confusing situation.

Adenosine triphosphate-dependent reactions require magnesium, and many enzymes in one-carbon metabolism depend directly or indirectly on micronutrients.

Yet normal biochemical dependence does not mean that magnesium deficiency is the cause of every SAMe response.

Supplement combinations often make interpretation impossible. A person may begin methylfolate, vitamin B12, trimethylglycine, magnesium, choline, creatine, and glycine within one week. When symptoms change, no individual cause can be identified.

For educational self-navigation, the safest interpretive principle is not a dosing protocol but an observation rule:

Change one nonessential variable at a time, use the lowest reasonable exposure, define what is being observed, and stop interpreting subjective effects as proof of enzyme activity.

This principle does not apply when a clinician has prescribed treatment for a diagnosed deficiency or inherited disorder. It applies to self-directed experimentation in uncertain contexts.

How to read a positive response

A positive response may mean:

• the person was deficient or had inadequate intake;
• the compound bypassed a constrained step;
• the compound had a pharmacologic effect;
• another pathway was affected;
• the dose altered sleep, energy, or expectation;
• the underlying condition naturally fluctuated.

The response increases interest in a hypothesis but does not confirm it.

How to read a negative response

A negative response may mean:

• the dose was too high;
• the formulation was unsuitable;
• the compound interacted with medication;
• the proposed pathway was not the main problem;
• the timing was poor;
• the person has a condition in which the supplement is inappropriate;
• the symptom was unrelated.

It does not automatically prove the opposite methylation state.

Controlled choline depletion and repletion

In controlled feeding studies, participants consumed diets with adequate choline and were then placed on low-choline diets. A subset developed increased liver fat, aminotransferase elevation, or muscle injury.

Abnormalities improved with choline repletion. Genetic variation and sex or menopausal status modified susceptibility.

What this supports:

• human choline requirements vary;
• deficiency can cause liver fat and injury;
• repletion can reverse deficiency-induced abnormalities.

What this does not support:

• diagnosing choline deficiency from any fatty liver finding;
• assuming a PEMT variant is causal;
• using high-dose choline without assessing total context.

SAMe in alcoholic cirrhosis

A randomized two-year trial in 123 patients with alcoholic cirrhosis reported a possible benefit in survival or transplantation-free outcome, particularly in less advanced disease, but interpretation was influenced by subgroup analysis. A later 24-week randomized trial in 37 abstinent patients found no advantage of SAMe over placebo, while abstinence itself improved liver function.

What this supports:

• biologic plausibility alone does not guarantee a consistent clinical effect;
• disease stage and primary-cause control matter;
• SAMe evidence is condition-specific and mixed.

Rare methylation disorders treated with methionine restriction

Published cases of S-adenosylhomocysteine hydrolase deficiency and adenosine kinase deficiency describe methionine restriction under specialist management, with biochemical improvement and variable clinical response.

What this supports:

• dietary methionine can be therapeutically manipulated in specific diagnosed disorders;
• monitoring SAM, SAH, methionine, growth, nutrition, and clinical status is essential.

What this does not support:

• applying severe methionine restriction to common fatigue, fatty liver, or supplement sensitivity;
• inferring a rare disorder from a common single-nucleotide polymorphism.

A pattern becomes harder to interpret when:

• multiple methyl donors are taken together;
• doses change every few days;
• liver enzymes are not rechecked after a suspected supplement injury;
• alcohol, medication, sleep apnea, metabolic disease, or thyroid dysfunction are not addressed;
• a person restricts protein despite weight loss or sarcopenia;
• a commercial algorithm is treated as more authoritative than standard clinical findings.

In these situations, simplification is often more informative than adding another cofactor.

Hepatic methionine and S-adenosylmethionine (SAM) metabolism is supported by well-established biochemistry.

The liver plays a major role in converting methionine into SAM, using SAM in methyltransferase reactions, clearing S-adenosylhomocysteine (SAH), remethylating homocysteine, supporting transsulfuration, and producing phosphatidylcholine.

It is also well established that different disturbances can produce different biochemical patterns. Reduced SAM production, SAH accumulation, impaired SAM buffering, persistent hypermethioninemia, and mixed changes in chronic liver disease should not be treated as one uniform state of “low” or “high” methylation.

The strongest evidence supports:

• the central roles of MAT1A, MAT2A, GNMT, AHCY, BHMT, and PEMT in hepatic methionine and SAM metabolism;
• altered methionine-cycle regulation in chronic liver disease;
• recognized inherited disorders involving MAT1A, GNMT, AHCY, and ADK;
• the ability of choline deficiency to cause liver fat and liver or muscle injury in susceptible people;
• the importance of interpreting liver, kidney, nutritional, and metabolic context together.

Evidence for supplements is more condition-specific.

SAMe, choline, betaine, methionine, methylfolate, glycine, and creatine may affect connected pathways, but a plausible biochemical mechanism does not establish that a supplement will be effective or appropriate for a particular person.

What the evidence does not support:

Current evidence does not support diagnosing hepatic methionine or SAM dysregulation from:

• fatigue, anxiety, brain fog, or another nonspecific symptom;
• one common genetic variant;
• one isolated metabolite;
• a commercial methylation score;
• improvement or worsening after a methyl donor;
• labels such as “overmethylation” or “undermethylation.”

A response to a supplement is information about that response. It is not a direct measurement of hepatic enzyme activity, intracellular SAM, SAH clearance, or methylation flux.

Essential safety guardrails

Persistent or marked hypermethioninemia should not be managed through unsupervised protein restriction or supplement trials. It may require evaluation for liver disease or an inherited metabolic disorder.

Kidney function should be considered whenever homocysteine, SAM, SAH, methylmalonic acid, or related metabolites are abnormal.

Normal aminotransferases do not exclude fatty liver or fibrosis. Standard liver assessment remains more important than speculative methylation interpretation.

More methyl donors are not automatically helpful. High SAH, impaired SAM buffering, renal dysfunction, or persistent hypermethioninemia may require a different interpretation from simple methyl-donor deficiency.

Common genetic variants are usually modifiers, not diagnoses. They do not directly measure enzyme activity or determine supplement requirements.

Severe methionine or protein restriction can cause nutritional harm. Therapeutic restriction is reserved for specific diagnosed disorders and requires professional monitoring.

Hepatic Methionine Metabolism and SAM Homeostasis Dysregulation is best understood as a family of liver-related biochemical disturbances rather than a single state of high or low methylation.

The pattern can involve:

• insufficient conversion of methionine into SAM;
• excessive or poorly buffered SAM;
• accumulation of SAH;
• altered remethylation through folate, vitamin B12, choline, or betaine pathways;
• increased or redistributed SAM demand;
• disturbed phosphatidylcholine synthesis and lipid export;
• altered transsulfuration and glutathione-related metabolism;
• secondary changes caused by liver disease, kidney dysfunction, nutrition, alcohol, medication, or systemic illness.

The strongest interpretation is built from converging evidence.

It begins with the exact finding, verifies technical quality, considers standard liver and renal explanations, distinguishes common from rare causes, and identifies the most plausible pathway node. It does not begin with a global label.

A person can have high methionine and low SAM. Another can have high methionine and very high SAM. A third can have normal SAM but elevated SAH. A fourth can have fatty liver with normal routine methylation markers. These are not contradictory versions of one simple condition. They are different biochemical situations that require different questions.

The responsible conclusion is therefore not that liver-related methylation changes are too complex to be useful. The responsible conclusion is that their usefulness depends on precision.

A response is information. A marker is a clue. A pathway model is a hypothesis. None of them, alone, is a diagnosis.

Core Hepatic Methionine and SAM Biology
1. Mato JM, Martínez-Chantar ML, Lu SC. S-adenosylmethionine metabolism and liver disease. Annals of Hepatology. 2013. Grade B. Comprehensive mechanistic review integrating human liver disease and experimental evidence.
2. Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. Physiological Reviews. 2012. Grade B. Authoritative review of MAT1A, MAT2A, GNMT, SAM homeostasis, liver injury, and carcinogenesis.
3. Ramani K, Lu SC. Methionine adenosyltransferases in liver health and diseases. Liver Research. 2017. Grade B. Review of methionine adenosyltransferase isoforms, the MAT1A/MAT2A switch, fibrosis, and cancer biology.
4. Li Z, Wang F, Liang B, Su Y, Sun S, Xia S, et al. Methionine metabolism in chronic liver diseases: an update on molecular mechanism and therapeutic implication. Signal Transduction and Targeted Therapy. 2020. Grade B. Detailed review of methionine-cycle remodeling across chronic liver diseases.
5. Frau M, Feo F, Pascale RM. Pleiotropic effects of methionine adenosyltransferases deregulation in liver cancer. International Journal of Molecular Sciences. 2013. Grade C. Mechanistic and translational evidence on methionine adenosyltransferase dysregulation in hepatocarcinogenesis.
6. Ji Y, Nordgren KK, Chai Y, Hebbring SJ, Jenkins GD, Abo RP, et al. Human liver methionine cycle: MAT1A and GNMT gene resequencing, functional genomics, and genotype-phenotype correlation. Drug Metabolism and Disposition. 2012. Grade B. Human genetic and functional study of MAT1A and GNMT variation.
Inherited Methylation Disorders
7. Barić I, Staufner C, Augoustides-Savvopoulou P, Chien YH, Dobbelaere D, Grünert SC, et al. Consensus recommendations for the diagnosis, treatment and follow-up of inherited methylation disorders. Journal of Inherited Metabolic Disease. 2017. Grade A. Formal consensus covering methionine adenosyltransferase I/III, GNMT, AHCY, and adenosine kinase deficiencies.
8. Chamberlin ME, Ubagai T, Mudd SH, Wilson WG, Leonard JV, Chou JY. Methionine adenosyltransferase I/III deficiency: novel mutations and clinical variations. American Journal of Human Genetics. 2000. Grade C. Human case series and molecular characterization.
9. Chien YH, Abdenur JE, Baronio F, Bannick AA, Corrales F, Couce M, et al. Mudd's disease (MAT I/III deficiency): a survey of data for MAT1A homozygotes and compound heterozygotes. Orphanet Journal of Rare Diseases. 2015. Grade B/C. Multicenter rare-disease survey with genotype and phenotype data.
10. Barić I, Fumić K, Glenn B, Cuk M, Schulze A, Finkelstein JD, et al. S-adenosylhomocysteine hydrolase deficiency in a human: a genetic disorder of methionine metabolism. Proceedings of the National Academy of Sciences. 2004. Grade C. Foundational human case and biochemical characterization.
11. Buist NRM, Glenn B, Vugrek O, Wagner C, Stabler S, Allen RH, et al. S-adenosylhomocysteine hydrolase deficiency in a 26-year-old man. Journal of Inherited Metabolic Disease. 2006. Grade C. Adult case demonstrating long-term multisystem expression.
12. Huang Y, et al. The biochemical profile and dietary management in S-adenosylhomocysteine hydrolase deficiency. Molecular Genetics and Metabolism Reports. 2022. Grade C. Case report plus synthesis of reported biochemical patterns.
13. Almuhsen N, et al. Clinical utility of methionine restriction in adenosine kinase deficiency. JIMD Reports. 2021. Grade C. Case-based evidence on dietary management in a rare disorder.
14. Barić I, et al. Glycine N-methyltransferase deficiency: a member of the expanding family of inherited disorders of methylation. Molecular Genetics and Metabolism. 2016. Grade C. Rare-disease review and patient evidence.
Liver-Disease Guidance and Clinical Context
15. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023. Grade A. Standard clinical assessment, fibrosis risk stratification, and management guidance.
16. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease. Journal of Hepatology. 2024. Grade A. Current European MASLD guidance.
17. Tang Y, et al. Association of serum methionine metabolites with non-alcoholic fatty liver disease. Nutrition and Metabolism. 2022. Grade B. Human observational evidence for altered circulating SAM, SAH, and homocysteine in fatty liver.
18. Piras IS, et al. Hepatic PEMT expression decreases with increasing severity of NAFLD in obese individuals and postmenopausal women. International Journal of Molecular Sciences. 2022. Grade B. Human liver-tissue study linking PEMT expression with disease severity.
19. Guerrerio AL, Colvin RM, Schwartz AK, Molleston JP, Murray KF, Diehl A, et al. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. American Journal of Clinical Nutrition. 2012. Grade B. Human cohort examining choline intake and histologic severity.
Choline, PEMT, and Controlled Human Evidence
20. da Costa KA, Kozyreva OG, Song J, Galanko JA, Fischer LM, Zeisel SH. Common genetic polymorphisms affect the human requirement for the nutrient choline. FASEB Journal. 2006. Grade A/B. Controlled human depletion-repletion study with genetic modifiers.
21. Sha W, da Costa KA, Fischer LM, Milburn MV, Lawton KA, Berger A, et al. Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline. FASEB Journal. 2010. Grade A/B. Controlled human feeding study with objective liver outcomes.
22. Mehedint MG, Zeisel SH. Choline's role in maintaining liver function: new evidence for epigenetic mechanisms. Current Opinion in Clinical Nutrition and Metabolic Care. 2013. Grade B. Review centered on human depletion studies and hepatic mechanisms.
23. Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Current Opinion in Gastroenterology. 2012. Grade B. Integrative review of choline, PEMT, very-low-density lipoprotein export, and fatty liver.
24. Li J, et al. Phosphatidylethanolamine N-methyltransferase: from functions to diseases. Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids. 2023. Grade B/C. Mechanistic review of PEMT and phosphatidylcholine biology.
25. Obeid R, et al. Choline: a scoping review for Nordic Nutrition Recommendations 2023. Food and Nutrition Research. 2023. Grade A/B. Evidence synthesis on choline requirements and health outcomes.
SAMe Intervention Evidence
26. Mato JM, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Journal of Hepatology. 1999. Grade A/B. Long-term randomized trial with subgroup-dependent findings.
27. Medici V, Virata MC, Peerson JM, Stabler SP, French SW, Gregory JF, et al. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research. 2011. Grade A. Randomized trial finding no added benefit over placebo during abstinence.
28. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database of Systematic Reviews. 2001. Grade A. Systematic review emphasizing limited and heterogeneous evidence.
29. Guo T, Chang L, Xiao Y, Liu Q. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. PLoS One. 2015. Grade A/B. Evidence synthesis across heterogeneous liver conditions.
30. Noureddin M, et al. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: a systematic review. World Journal of Hepatology. 2020. Grade A/B. Review of biochemical and symptom outcomes in cholestasis.
31. Baden KER, et al. S-Adenosylmethionine for liver health: a systematic review. Nutrients. 2024. Grade A/B. Recent systematic review, interpreted cautiously because included conditions and outcomes are heterogeneous.
Measurement and Interpretation
32. Adaikalakoteswari A, et al. Simultaneous detection of five one-carbon metabolites in plasma by liquid chromatography-tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine. 2016. Grade B. Analytical study of SAM, SAH, methionine, homocysteine, and methylmalonic acid measurement.
33. Bravo AC, et al. Method optimisation and profiling of S-adenosylmethionine and S-adenosylhomocysteine in healthy adults. Nutrients. 2022. Grade B. Methodological and reference-profile evidence.
34. Klepacki J, Brunner N, Schmitz V, Klawitter J, Christians U. Development and validation of an LC-MS/MS assay for the determination of SAM and SAH in human plasma. Journal of Chromatography B. 2013. Grade B. Analytical validation and discussion of clinical confounders.
35. Hao X, et al. Immunoassay of S-adenosylmethionine and S-adenosylhomocysteine in human plasma. Clinical Chemistry and Laboratory Medicine. 2016. Grade B. Measurement study examining liver-disease associations.
36. Kruglova MP, et al. The diagnostic and prognostic roles played by homocysteine, SAM, SAH, and their ratios in chronic kidney disease. International Journal of Molecular Sciences. 2023. Grade B. Review and human evidence on renal confounding.
Mechanistic and Translational Support
37. Martinez-Uña M, et al. S-adenosylmethionine increases circulating very-low-density lipoprotein clearance in non-alcoholic fatty liver disease. Journal of Hepatology. 2015. Grade B/C. Translational work linking hepatic SAM, PEMT, and lipid export.
38. Ye C, Sutter BM, Wang Y, Kuang Z, Tu BP. A metabolic function for phospholipid and histone methylation. Molecular Cell. 2017. Grade C. Experimental evidence connecting SAM availability with competing methylation demands.
39. Walker AK. 1-carbon cycle metabolites methylate their way to fatty liver. Trends in Endocrinology and Metabolism. 2017. Grade B/C. Integrative review of one-carbon metabolism and hepatic lipid accumulation.
40. Schalinske KL, Smazal AL. Homocysteine imbalance: a pathological metabolic marker. Advances in Nutrition. 2012. Grade B. Review of homocysteine, SAH, remethylation, and transsulfuration.